|
May 12, 2022
|
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
|
|
|
May 11, 2022
|
Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
|
|
|
May 9, 2022
|
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
|
|
|
May 3, 2022
|
Caribou Biosciences to Present at Upcoming Investor Conference
|
|
|
May 2, 2022
|
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
|
|
|
April 25, 2022
|
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
|
|
|
April 8, 2022
|
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
|
|
|
March 21, 2022
|
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
|
|
|
March 8, 2022
|
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
|
|
|
March 7, 2022
|
Caribou Biosciences to Present at Upcoming Investor Conferences
|
|
